Photo by BRI72783 via Wikimedia Commons There is greater appreciation of potential comorbidities in patients with hidradenitis suppurativa (HS), both in the adult and pediatric setting, according to a special report in the June 2026 edition of The Chronicle of Skin & Allergy. Comorbidities are common in patients with HS, and some of the most challenging to manage include inflammatory bowel disease, inflammatory arthritis, polycystic ovary syndrome, metabolic syndrome, depre

Dr. Irena Pastar and Dr. Hadar Lev-Tov. Photo courtesy Miller School of Medicine Physicians at the University of Miami Miller School of...

On Oct. 30, 2024, the American Academy of Dermatology (AAD) announced a new initiative to shed light on hidradenitis suppurativa (HS). In...

A study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam has revealed the potential of...

Recent research has found smoking cessation significantly reduced the risk of developing hidradenitis suppurativa (HS). The findings were...

Researchers have identified genetic risk loci that contribute to the genetic risk of developing hidradenitis suppurativa (HS). The...

Patients with moderate to severe hidradenitis suppurativa (HS) treated with secukinumab demonstrate sustained efficacy and symptom...

New research from France has shown that about two-thirds of patients with chronic inflammatory skin diseases such as adult acne, atopic...